LPL Financial
RLMD icon

LPL Financial’s Relmada Therapeutics RLMD Stock Holding History

LPL Financial’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,490
Closed -$43.7K – 5411
2024
Q3 		$43.7K Sell
13,490
-1,938
-13% -$6.28K ﹤0.01% 5014
2024
Q2 		$46.3K Buy
15,428
+2,933
+23% +$10.6K ﹤0.01% 4845
2024
Q1 		$58.1K Sell
12,495
-1,190
-9% -$5.73K ﹤0.01% 4751
2023
Q4 		$56.7K Buy
13,685
+725
+6% +$2.15K ﹤0.01% 4635
2023
Q3 		$38.9K Buy
+12,960
New +$38.5K ﹤0.01% 4545

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial's RLMD Position: Q4 2024 in Review

LPL Financial sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 13,490 shares — an estimated $43.7K sold.

LPL Financial first reported a position in RLMD in Q3 2023 and held it in 5 quarters. The position peaked at $58.1K in Q1 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • LPL Financial reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • LPL Financial sold 13,490 Relmada Therapeutics shares in Q4 2024, an estimated $43.7K.
  • LPL Financial first reported a position in Relmada Therapeutics in Q3 2023 and held it in 5 quarters.
  • LPL Financial's Relmada Therapeutics position peaked at $58.1K in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on LPL Financial's 13F filing for Q4 2024, filed 11 Feb 2025.